Last reviewed: June 16, 2026
Last updated: June 16, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Type 1 diabetes requires insulin replacement, but emerging research suggests GLP-1 receptor agonists like semaglutide may reduce daily insulin doses and stabilize blood glucose patterns. While semaglutide is FDA-approved for type 2 diabetes and weight loss, its use in type 1 diabetes represents a newer frontier that endocrinologists are exploring with growing interest.
How Semaglutide Affects Type 1 Diabetes Management
Semaglutide activates GLP-1 receptors in the pancreas, gut, and brain, triggering three key responses: it slows stomach emptying, reduces appetite, and enhances insulin secretion from remaining beta cells. In type 1 diabetes, where the immune system destroys insulin-producing cells, semaglutide cannot replace insulin—but it can improve how existing insulin works and reduce the total daily dose patients require. Clinical observations show that adding semaglutide to an insulin regimen often lowers hemoglobin A1C levels by 0.5–1.5% while decreasing insulin requirements by 15–30%.
The mechanism behind this effect involves improved glucose sensitivity and delayed gastric emptying, which smooths postprandial blood sugar spikes. Patients using semaglutide alongside insulin report fewer hypoglycemic episodes and greater glucose stability, particularly around meals. However, semaglutide is not a substitute for insulin in type 1 diabetes—insulin remains the foundation of treatment, with semaglutide serving as an adjunctive therapy under close medical supervision.
Clinical Evidence for Type 1 Diabetes Use
While semaglutide carries an FDA indication for type 2 diabetes and chronic weight management, its use in type 1 diabetes is considered off-label. Several small clinical studies and real-world case series have examined this application, showing encouraging but preliminary results. A 2023 analysis of type 1 patients receiving semaglutide demonstrated an average 0.8% reduction in A1C and a 20% decrease in total daily insulin doses over 24 weeks, alongside modest weight loss in overweight participants.
Endocrinologists emphasize that type 1 diabetes presents unique challenges when using GLP-1 agonists, including the risk of diabetic ketoacidosis (DKA) if insulin is reduced too aggressively or if nausea limits food intake. Ongoing randomized controlled trials are underway to establish optimal dosing protocols, safety thresholds, and patient selection criteria. Until phase 3 trials are complete, any off-label use requires close glucose monitoring, regular insulin adjustments, and experienced clinical oversight.
Semaglutide Dosing and Insulin Adjustment in Type 1 Diabetes
Initiating semaglutide in type 1 diabetes demands a cautious, individualized approach because rapid insulin reduction can trigger DKA, a medical emergency. Most endocrinologists begin with a low microdose of semaglutide (0.25 mg weekly) while simultaneously reducing basal and bolus insulin by 10–20% based on continuous glucose monitor readings. The dose typically escalates by 0.25 mg every 1–2 weeks, with insulin adjustments made in real-time to maintain target glucose ranges and prevent dangerous lows.
PlexusDx offers a Microdose GLP-1 Protocol at $129/month for patients seeking lower-dose, precisely titrated semaglutide therapy, which aligns with conservative type 1 diabetes protocols. Standard Compounded Semaglutide Injection begins at $149/month and includes options for careful, physician-guided dose escalation. Regular blood sugar logs, continuous glucose monitoring data, and frequent provider check-ins (weekly to biweekly) are essential during the initiation phase to ensure safe insulin tapering and sustained glycemic control.
Safety Considerations and Risk Mitigation
The primary safety concern with semaglutide in type 1 diabetes is diabetic ketoacidosis, which can develop if insulin is reduced too quickly or if semaglutide-induced nausea reduces food intake without corresponding insulin cuts. Other side effects include gastrointestinal symptoms (nausea, vomiting, diarrhea), pancreatitis risk (rare but serious), and potential thyroid effects in predisposed individuals. Patients must have reliable glucose monitoring technology (CGM), understand DKA warning signs, and commit to frequent medical follow-up.
PlexusDx recommends that all type 1 diabetes patients considering compounded semaglutide obtain clearance from their endocrinologist and engage in shared decision-making about risks and benefits. The Precision Peptide Genetic Test (a $99 add-on available after the first month of treatment) identifies genetic variations in GLP1R, GIPR, FTO, and MC4R pathways—insights that may inform individual semaglutide responsiveness and metabolic risk factors. Genetic predispositions alone do not determine safety in type 1 diabetes, but they contribute to a personalized risk–benefit profile that guides dosing decisions.
The Future of GLP-1 Therapy in Type 1 Diabetes
Ongoing clinical trials are investigating whether newer GLP-1 formulations, combination therapies (such as GLP-1 plus glucagon receptor agonists), and dual agonists like tirzepatide can further optimize glucose control and reduce insulin burden in type 1 diabetes. Preliminary data suggest that combination approaches may offer additive benefits beyond single-agent GLP-1 use, though long-term safety and efficacy remain under evaluation. The field is moving toward precision medicine models that match individual genetic profiles, pancreatic reserve capacity, and comorbidity status to the most effective treatment regimen.
PlexusDx supports this precision approach through compounded semaglutide and tirzepatide options designed for personalized dosing, combined with genetic insights from the Precision Peptide Genetic Test. As evidence accumulates and regulatory pathways evolve, GLP-1 agonists may become standard adjunctive therapy for select type 1 diabetes patients—particularly those with insulin resistance, overweight status, or suboptimal glycemic control on insulin alone. Type 1 patients interested in exploring GLP-1 therapy should consult their endocrinologist and consider accessing PlexusDx through state-licensed 503A compounding pharmacies available in all 50 states.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is semaglutide FDA-approved for type 1 diabetes?
No, semaglutide is not FDA-approved for type 1 diabetes; its approval covers type 2 diabetes and chronic weight management. Use in type 1 diabetes is off-label and requires endocrinologist oversight. PlexusDx compounded semaglutide is not FDA-approved but is prepared by licensed 503A compounding pharmacies and prescribed off-label under medical supervision.
How much can semaglutide reduce insulin requirements in type 1 diabetes?
Published case series show insulin reductions of 15–30% in type 1 patients receiving semaglutide, alongside A1C decreases of 0.5–1.5%. Individual results vary widely depending on baseline insulin sensitivity, body weight, and disease duration. Reductions must be made cautiously under close glucose monitoring to prevent dangerous lows or ketoacidosis.
Can I get semaglutide for type 1 diabetes through PlexusDx?
Yes, PlexusDx offers Compounded Semaglutide Injection starting at $149/month from licensed 503A pharmacies, available in all 50 states without insurance requirements. You must have a valid prescription from your endocrinologist; PlexusDx does not diagnose or treat but dispenses physician-prescribed medications and accepts HSA/FSA payments.
What are the main risks of semaglutide in type 1 diabetes?
The primary risk is diabetic ketoacidosis (DKA) if insulin is reduced too aggressively or if nausea limits food intake. Other risks include pancreatitis, severe GI side effects, and potential thyroid concerns in genetically predisposed individuals. Close glucose monitoring, frequent provider contact, and patient education on DKA warning signs are essential safeguards.
How can the Precision Peptide Genetic Test help with type 1 diabetes GLP-1 therapy?
The Precision Peptide Genetic Test ($99 add-on) identifies variants in GLP1R, GIPR, FTO, and MC4R pathways that influence individual metabolic response and peptide sensitivity. While not a pharmacogenomic test, these insights help your provider personalize semaglutide dosing and predict your likelihood of meaningful A1C reduction and insulin savings, supporting safer, more precise treatment planning.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Optimizing Your Health Journey: What You Can Take with Tirzepatide
What Supplements Should You Take on GLP-1?